Sugi Predict

Sugi Predict / Compounds / SCHEMBL1497714

SCHEMBL1497714

SCHEMBL1497714

CC1(C)CCC(c2ccc(Cl)cc2)=C(C=O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 6/20 0.44
▸ PTGS1 P23219 4/20 0.44
▸ BCL2L1 Q07817 1/20 0.41
▸ BCL2 P10415 3/20 0.37
▸ SLC6A3 Q01959 4/20 0.34
▸ HSD17B10 Q99714 2/20 0.33
▸ ALPL P05186 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ MAPT P10636 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ PTK2B Q14289 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1700136 0.88 PTGS2 (0.48) PTGS2PTGS1BCL2L1BCL2SLC6A3
SCHEMBL1958631 0.85 PTGS2 (0.55) PTGS2PTGS1SLC6A3HSD17B10ALPL
SCHEMBL28417328 0.84 PTGS2 (0.44) PTGS2PTGS1ALPLALDH1A1KDM4E
SCHEMBL28441891 0.84 NPC1 (0.38) PTGS2BCL2L1KMT2AALDH1A1HPGD
SCHEMBL15539299 0.83 PTGS2 (0.44) PTGS2PTGS1BCL2L1SLC6A3HSD17B10
SCHEMBL1701087 0.82 PTGS2 (0.38) PTGS2PTGS1BCL2L1SLC6A3HSD17B10
SCHEMBL15920816 0.82 PGR (0.40) SLC6A3SLC6A2KMT2AMEN1
SCHEMBL26647998 0.81 SLC6A3 (0.39) PTGS2PTGS1BCL2L1BCL2SLC6A3
SCHEMBL1701049 0.81 PTGS2 (0.37) PTGS2PTGS1BCL2L1SLC6A3HSD17B10
SCHEMBL29318065 0.81 PTGS2 (0.40) PTGS2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307393-B1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LAB (US) 2013-04-10 — — EP claimed
US-8168784-B2 Processes to make apoptosis promoters ABBOTT LABORATORIES (US) 2012-05-01 — — US claimed
JP-2011525182-A — — 2011-09-15 — — JP claimed
EP-2307393-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 Abbott Laboratories (US) 2011-04-13 — — EP claimed
US-20090318689-A1 Processes To Make Apoptosis Promoters ABBOTT LABORATORIES (US) 2009-12-24 — — US claimed
WO-2009155386-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LABORATORIES (US) 2009-12-23 — — WO claimed
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 — — US disclosed
EP-4682148-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2026-01-21 — — EP disclosed
US-20250368603-A1 PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS ABBVIE INC (US) 2025-12-04 — — US disclosed
US-20250161318-A1 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT ABBVIE INC (US) 2025-05-22 — — US disclosed
EP-4522154-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
US-12220419-B2 BCL-2 inhibitors NEWAVE PHARMACEUTICAL INC. (US) 2025-02-11 — — US disclosed
US-20250019364-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2025-01-16 — — US disclosed
WO-2010065824-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 — — WO disclosed
WO-2010065865-A2 BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 — — WO disclosed
US-20090318689-A1 Processes To Make Apoptosis Promoters ABBOTT LABORATORIES (US) 2009-12-24 — — US disclosed
US-20090318689-A1 Processes To Make Apoptosis Promoters ABBOTT LABORATORIES (US) 2009-12-24 — — US disclosed
US-20090318689-A1 Processes To Make Apoptosis Promoters ABBOTT LABORATORIES (US) 2009-12-24 — — US disclosed
WO-2009155386-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LABORATORIES (US) 2009-12-23 — — WO disclosed
WO-2009155386-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LABORATORIES (US) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368603-A1 PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS BAX, CASP3, AIFM1 PTGS2 577/4885PTGS1 360/4885BCL2L1 25/4885
US-20090318689-A1 Processes To Make Apoptosis Promoters BAX, BCL2, CCAR2 PTGS2 2110/4885PTGS1 1680/4885BCL2L1 28/4885
US-20250019364-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BCL2, BAX, BCL3 PTGS2 171/4885PTGS1 257/4885BCL2L1 4/4885
US-12220419-B2 BCL-2 inhibitors BCL2L10, BCL2, BCL2L11 PTGS2 623/4885PTGS1 519/4885BCL2L1 4/4885
US-20250161318-A1 SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT BCL2, BAX, BCL2L1 PTGS2 2007/4885PTGS1 2722/4885BCL2L1 3/4885
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 PTGS2 178/4885PTGS1 197/4885BCL2L1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.